Cynthia Collins

May 25, 2018

DermTech, a developer of non-invasive molecular dermatology tests, has appointed Cynthia Collins to its board of directors. Collins most recently served as CEO of Human Longevity. She has also been CEO/GM of GE Healthcare's cell therapy business, lab businesses, and Clarient Diagnostics. Prior to GE, Collins was president and CEO of GenVec. Before that she was group vice president for the cellular analysis business at Beckman Coulter. She has also held executive positions with Sequoia Pharmaceuticals and Clinical Micro Sensors, a subsidiary of Motorola.

Cynthia Collins

Grail Q1 Revenues up 19 Percent Driven by Clinical Test Growth

Seer Q1 Revenues Rise 35 Percent

Biodesix Q1 Revenues up 21 Percent as Firm Slashes Full-Year Guidance on Sales Restructuring

MantaBio Nabs $2.5M in Seed Funding to Develop Microbial Detection Platform for Biopharma

Socioeconomic Factors, Not Genetic Ancestry, Linked to All-Cause Mortality in Black Americans